Recommendations support Calquence plus bendamustine and rituximab for older patients with previously untreated mantle cell lymphoma, highlighting treatment eligibility criteria.
Canada’s Drug Agency (CDA-AMC) recommends that Calquence should be reimbursed by public drug plans for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplant (ASCT) in combination with bendamustine and rituximab (BR), if certain conditions are met. Calquence plus BR should only be covered to treat patients aged 65 years or older with previously untreated MCL, with a good performance status. Calquence plus BR should not be covered in patients who have a history of central nervous system lymphoma or leptomeningeal disease, or if the goal of therapy is tumour debulking before stem cell transplant. Calquence plus BR should only be reimbursed if prescribed by clinicians with expertise in managing MCL and monitoring therapy, and if the cost of Calquence is reduced.
No takes yet. Share an insight, caveat, or question.
CDA-AMC (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: